Press Room

    Back

    Press Release - July 28, 2006

    Business Advisory Board Established to Commercialize Diabetes Product


    Kelowna, B.C. -- Pheromone Sciences Corp. ("Pheromone") is pleased to announce that it has established a Business Advisory Board to strategically guide the directors and management in commercializing the Company's diabetes product. Pheromone has appointed three former Company directors to the board: William Milligan, Andrew Saxton and Christopher Neuman.

    "These men all have an intimate understanding of the Company and the business of biotechnology," said Dr. William Cochrane, Chairman of the Board of Directors. "We are glad Pheromone will continue to get the benefit of their expertise and wisdom."

    About William Milligan Since 2002 Mr. Milligan has served as the Chief Business Officer of Migenix Inc. (TSX: MGI), a biopharmaceutical company focused on innovative drugs for life- threatening diseases. He has extensive experience in leading and managing pharmaceutical commercialization, financing, product development, licensing and strategic alliances from both large pharmaceutical and small biotechnology companies. Mr. Milligan was previously President & CEO of Cytran Inc., a private biotechnology company based in Seattle, and CEO of Intellivax International Inc., a private biotechnology company based in Montreal and Baltimore. Prior to that he worked for Hoffmann-La Roche Ltd. (Canada) and Eli Lilly Inc. (Canada). At Roche, he held Vice President positions in Pharmaceuticals including: Business Development and New Product Planning, Sales Division, and Biomedical Division. Mr. Milligan served as a Director of Pheromone from 2000-2006.

    About Andrew Saxton Mr. Saxton is currently Chairman of the King George Financial Corporation and has had a long and successful career of leadership roles in finance, commercial real estate and insurance. He is currently a Director of Canadian Commercial Corporation (a Federal Crown Corporation), Earthworks Industries Inc., Imperial Parking Canada Corporation, and the University of British Columbia Investment Management Trust. He was previously the co-founder and Executive Vice President of Laurentide Financial Corporation, founder and President of Elite Insurance and Chairman of Grouse Mountain Resorts Ltd. He has been a Director with of several companies including BCTV, the Commonwealth Bank of Nassau Bahamas, and the Insurance Corporation of British Columbia, where he chaired the Investment Committee. He has served on many advisory boards including the World Heart Federation, the BC Life Sciences Fund and the Dean of Faculty of Medicine's Community Advisory board at the University of British Columbia. From 2000- 2006 Mr. Saxton was a director of Pheromone.

    About Christopher Neuman Mr. Neuman was a director of Pheromone from 2000 to 2006, serving as its CEO until 2005. He has 35 years experience in the Canadian health care industry, including positions as General Manager of ALZA Canada, and President and General Manager of Baker Cummins Inc. He held senior management positions with Marion Merrell Dow Inc., PharmaScience Inc., Boots Pharmaceuticals Ltd. and Neuromedical Systems Inc., where, as General Manager, he was responsible for the establishment of a Canadian subsidiary for the U.S. diagnostics company. His early career included production & operations management, positions at Davis+Geck/Lederle Laboratories, Elliot-Marion Co. Ltd., and sales and sales & marketing management positions at Beecham Laboratories Inc.

    Pheromone Sciences Corp. is a biotechnology research and development company focused on commercializing medical technologies.



    ON BEHALF OF THE BOARD

    "Dev Randhawa"

    Dev Randhawa, CEO

    For further information contact: Mr. Phil Morehouse Pheromone Sciences Corp. TEL: (250) 868-8177 FAX: (250) 868-8493

    Back



    Press Releases from:

    2017 2016 2015 2014 2013 2012 2011

    2010 2009 2008 2007 2006 2005 2004

    2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs

    Link

    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance

    PDF

    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario

    Link

    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Publisher: StockInterview.com
    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Publisher: StockInterview.com
    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Publisher: StockInterview.com
    Author: James Finch

    Presentation and Video

    September 11, 2017

    Sernova Fact Sheet

    September 11, 2017

    Sernova's 2017 Corporate Presentation

    PDF Presentation

    Subscribe to Sernova News

Subscribe to our News Dispatch Service

* indicates required




Latest Video and Presentation


Sernova Fact Sheet - / September 11, 2017 Open


Sernova's 2017 Corporate Presentation - PDF Presentation / September 11, 2017 Open

All Presentations →